Qube Research & Technologies LTD Lipocine Inc. Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 01, 2022	SELL	$0.99 - $1.2 $23,834 - $28,890	-24,075 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$1.08 - $1.49 $26,001 - $35,871	24,075 New	24,075 $26,000
Q2 2021 Aug 13, 2021	SELL	$1.17 - $1.59 $27,590 - $37,495	-23,582 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$1.38 - $2.28 $135,169 - $223,323	-97,949 Reduced 80.6%	23,582 $36,000
Q4 2020 Feb 16, 2021	SELL	$1.2 - $1.69 $223,996 - $315,462	-186,664 Reduced 60.57%	121,531 $165,000

Q3 2020 Nov 12, 2020	BUY	$1.21 - $2.23 $306,024 - $563,995	252,913 Added 457.5%	308,195 $435,000
Q2 2020 Aug 14, 2020	BUY	$0.42 - $1.26 $23,218 - $69,655	55,282 New	55,282 $70,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $729M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.